An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate

NCT ID: NCT01844869

Last Updated: 2015-01-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-07-31
• Study Completion Date: 2015-01-31

Brief Summary

The purpose of this study is to determine the pharmacokinetic and safety profiles of omacetaxine and its metabolites in patients with relapsed and/or refractory hematologic malignancies or advanced solid tumors following subcutaneous (sc) administration.

Detailed Description

This is a Phase 1, single-center, open-label, nonrandomized study to determine the pharmacokinetics (absorption, distribution, metabolism, and excretion) of omacetaxine and its metabolites following a sc dosage of 1.25 mg/m2 in adult patients with relapsed and/or refractory hematologic malignancies or advanced solid tumors. The study consists of a screening period of up to 28 days, followed by a 7-day pharmacokinetic assessment period (period A) that includes administration of a single radiolabeled dose of omacetaxine, an open-label treatment period of up to six 28-day cycles (period B), and a final assessment to occur approximately 28±7 days after the end of the last treatment cycle. Period B will begin after collection of the 72-hour pharmacokinetic sample during period A.

Conditions

Hematologic Malignancies; Solid Tumors

Keywords

omacetaxine; omacetaxine mepesuccinate; pharmacokinetics; hematologic malignancies; advanced solid tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

omacetaxine mepesuccinate

Period A: 7-day pharmacokinetic assessment period in which all patients will be administered a single subcutaneous radiolabeled dose of 1.25-mg/m2 omacetaxine.

Period B: omacetaxine will be administered as an sc injection at a dosage of 1.25 mg/m2 twice daily for 7 days (patients with solid tumors) or 14 days (patients with hematologic malignancies) of every 28-day cycle for up to 6 cycles.

Group Type: EXPERIMENTAL

omacetaxine mepesuccinate

Intervention Type: DRUG

Interventions

omacetaxine mepesuccinate

Intervention Type: DRUG

Other Intervention Names

omacetaxine

Eligibility Criteria

Inclusion Criteria

• Written informed consent is obtained.
• The patient is at least 18 years of age at the time of informed consent.
• The patient has a histologically or cytologically confirmed diagnosis of any of the following:
• Relapsed or refractory leukemia, including Philadelphia chromosome-positive (Ph+), chronic myelogenous leukemia (CML), acute promyelocytic leukemia (APL), acute myelogenous leukemia (AML), or myelodysplastic syndrome (MDS).
• Advanced solid tumors (ie, breast, lung, head/neck, colorectal, melanoma, and sarcoma). The malignancy must be considered unresponsive to accepted available therapies.
• The patient has an estimated life expectancy of at least 3 months.
• The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
• Other criteria apply.

Exclusion Criteria

• The patient has had chemotherapy, radiotherapy, radioimmunotherapy, or immunotherapy within 28 days prior to the first dose of study drug or has not recovered from adverse events due to any agents administered previously. For patients who received therapy with mitomycin C, the interval is 42 days.
• The patient is receiving any other treatment for hematologic/nonhematologic malignancy.
• The patient has had previous treatment with omacetaxine.
• The patient has been treated with any hematopoietic growth factors within 14 days of study entry (patients on chronic erythropoiesis stimulating agents are allowed).
• The patient has New York Heart Association (NYHA) Class 3 or 4 heart disease, active ischemia, or any uncontrolled, unstable cardiac condition for which treatment for the condition is indicated but is not controlled despite adequate therapy, including angina pectoris, cardiac arrhythmia, hypertension, or congestive heart failure.
• The patient has experienced a myocardial infarction within the previous 12 weeks.
• The patient has a solid tumor with symptomatic central nervous system (CNS) metastases.
• The patient has an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment.
• Other criteria apply.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Teva Investigational Site 38045

Amsterdam, , Netherlands

Countries

Netherlands

Other Identifiers

2012-004003-12

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

C41443/1103 Study

Identifier Type: -

Identifier Source: org_study_id